|
Patent landscape, scope, and claims: |
Scope and Claims of US Patent 7,635,707 (Pirfenidone Dose Modifications for Liver Biomarker Abnormalities in IPF)
US 7,635,707 is a US-method patent built around managing pirfenidone hepatotoxicity signals in idiopathic pulmonary fibrosis (IPF). The claims cover (i) treating IPF by administering pirfenidone when a patient has exhibited a grade 2 liver-function biomarker abnormality after prior pirfenidone exposure and (ii) specific dosing regimens at either 2400/2403 mg/day or 1600/1602 mg/day, with optional interruptions until biomarkers normalize and operational details like three-times-daily dosing with food and biomarker monitoring (ALT/AST, with bilirubin/alkaline phosphatase in dependent coverage).
What does US 7,635,707 claim cover for pirfenidone hepatotoxicity management in IPF?
Answer (claim core): A method for administering pirfenidone to IPF patients who develop grade 2 liver-function biomarker abnormalities after pirfenidone, using defined daily dose levels (2400/2403 mg/day or 1600/1602 mg/day) and optional hold-and-resume steps until biomarkers normalize, with optional monitoring and biomarker selection.
Claim architecture: two independent claim families by dose
- One claim family is directed to 2400 mg/day or 2403 mg/day dosing in the presence of grade 2 liver biomarker abnormality post-pirfenidone.
- The second claim family is directed to 1600 mg/day or 1602 mg/day dosing in the presence of grade 2 liver biomarker abnormality post-pirfenidone.
- Both families include closely aligned dependent claim options covering discontinuation until normalization, dosing frequency with food, biomarker selection, and biomarker measurement during administration.
Key limitation set for literal infringement risk
Across claim 1 and claim 7, infringement hinges on all of the following in combination:
- Indication: idiopathic pulmonary fibrosis (IPF).
- Patient status: the patient has “exhibited a grade 2 abnormality in one or more biomarkers of liver function after pirfenidone administration.”
- Drug: pirfenidone.
- Dose: either 2400/2403 mg/day or 1600/1602 mg/day depending on the claim.
- (Optionally, dependent claims) operational features like discontinuation/hold until normalization, stepwise prior dosing at 800/801 mg/day, three-times-daily with food, and specified biomarker sets.
What are the exact claim elements and dosing triggers in US 7,635,707?
Answer (elements): The patent claims a clinician’s method that ties together a biomarker-triggered clinical decision (grade 2 abnormality after prior pirfenidone) and a specific pirfenidone re-initiation dose (2400/2403 or 1600/1602 mg/day), with dependent coverage for hold/resume and monitoring.
Independent claim 1: 2400/2403 mg/day at grade 2 liver biomarker abnormality
Claim 1 requires:
- A method of administering pirfenidone to treat IPF.
- Patient has exhibited grade 2 abnormality in one or more liver-function biomarkers after pirfenidone administration.
- Administer pirfenidone at 2400 mg/day or 2403 mg/day.
Dependent claims add:
- Claim 2: discontinue pirfenidone prior to dosing until biomarkers are within normal limits.
- Claim 3: administer three times per day with food.
- Claim 4: biomarkers selected from ALT, AST, bilirubin, alkaline phosphatase.
- Claim 5: measure one or more biomarkers during dosing step.
- Claim 6: biomarker subset: ALT and AST.
Independent claim 7: 1600/1602 mg/day at grade 2 liver biomarker abnormality
Claim 7 requires:
- A method of administering pirfenidone to treat IPF.
- Patient has exhibited grade 2 abnormality in one or more liver-function biomarkers after pirfenidone administration.
- Administer pirfenidone at 1600 mg/day or 1602 mg/day.
Dependent claims add a stepwise clinical pattern:
- Claim 8: discontinue prior to dosing until biomarkers are within normal limits.
- Claim 9: prior to step (a), administer about 800 mg/day or 801 mg/day for about one week, or until biomarkers normalize.
- Claim 10: discontinue for about one week or until biomarkers normalize, then administer about 800 mg/day or 801 mg/day for about one week.
- Claim 11: administer three times per day with food.
- Claim 12: biomarkers selected from ALT, AST, bilirubin, alkaline phosphatase.
- Claim 13: measuring biomarkers during dosing.
- Claim 14: biomarker subset: ALT and AST.
Practical claim “decision tree” embedded in the language
The patent effectively encodes a re-dosing pathway:
- Trigger: post-pirfenidone grade 2 liver biomarker abnormality.
- Immediate re-initiation dose: either
- 2400/2403 mg/day (claim 1), or
- 1600/1602 mg/day (claim 7),
- With optional dependent features:
- hold until normalization (claims 2 and 8),
- include a reduced intermediate period at ~800 mg/day and about one week duration before stepping up or continuing (claims 9 and 10),
- monitor biomarkers during the dosing period (claims 5 and 13),
- specify dosing schedule and food administration (claims 3 and 11),
- define biomarker sets (claims 4/6 and 12/14).
How broad is US 7,635,707 in biomarker coverage and monitoring?
Answer: The patent uses a tiered biomarker definition that expands coverage beyond just transaminases to include bilirubin and alkaline phosphatase, while also creating narrower dependent claim embodiments limited to ALT/AST.
Biomarker scope by claim set
| Claim |
Biomarker limitation type |
Biomarkers expressly covered |
| 1 / 7 |
“one or more biomarkers of liver function” (generic) |
Not restricted at independent level in your provided text |
| 4 |
dependent, expanded set |
ALT, AST, bilirubin, alkaline phosphatase |
| 6 |
dependent, narrower set |
ALT, AST |
| 12 |
dependent, expanded set |
ALT, AST, bilirubin, alkaline phosphatase |
| 14 |
dependent, narrower set |
ALT, AST |
| 5 / 13 |
monitoring limitation |
“measuring one or more biomarkers of liver function during step (a)” |
Scope implications for infringement strategy
- Broadest literal coverage is at independent claim level because the biomarker phrase is “one or more” (without restricting to specific biomarkers) in claim 1 and claim 7 as you provided them.
- Dependent claims tighten biomarker identity to ALT/AST only or include bilirubin/alkaline phosphatase, strengthening enforceability against specific clinical protocols using those panels and monitoring routines.
What dosing regimens are protected: 2400 vs 1600 vs 800 mg/day step logic?
Answer: US 7,635,707 locks in two specific “re-initiation” dose levels (2400/2403 and 1600/1602 mg/day) for grade 2 liver biomarker abnormality, plus an optional dependent intermediate reduced dosing at ~800/801 mg/day for about one week.
Dose granularity
- Exact/restricted daily dose language: “2400 mg/day or 2403 mg/day” and “1600 mg/day or 1602 mg/day.”
- Approximate reduced dose language: “about 800 mg/day or 801 mg/day” for about one week, or until normalization.
- Frequency with food: “three times per day with food” in dependent claims.
Claim overlap and how they map to clinical titration
- The 2400/2403 regimen (claim 1 family) is a direct re-dose at a high daily dose under the trigger condition.
- The 1600/1602 regimen (claim 7 family) is a mid-dose strategy and is tied to step-down/step-up constructs using ~800/801 mg/day (claims 9 and 10).
What operational steps does US 7,635,707 add: hold, resume, monitoring, and food?
Answer: Dependent claims incorporate common clinical operational elements that make the method patent more enforceable against real-world practice: stopping until normalization, administering three times daily with food, and measuring liver biomarkers during treatment.
Operational features by claim
| Dependent claim |
Operational limitation |
Effect on scope |
| 2 / 8 |
discontinue until biomarkers are within normal limits |
Adds a clear “hold” step tied to a normalization endpoint |
| 3 / 11 |
three times per day with food |
Locks dosing schedule and administration condition |
| 5 / 13 |
measuring biomarkers during step (a) |
Requires active monitoring during the re-initiation dosing |
| 9 / 10 |
800/801 mg/day for ~1 week and hold/resume timing |
Defines a sequence and duration, raising enforceability for structured titration algorithms |
How strong is US 7,635,707 likely to be against design-around dosing?
Answer: Strength is driven by the use of multiple fixed dose endpoints (2400/2403, 1600/1602) paired with conditional clinical triggers (grade 2 abnormality after prior dosing), plus optional but specific operational features (hold until normalization, three-times-daily with food, biomarker measurement, and defined biomarker sets).
Design-around levers that would plausibly reduce literal coverage (at least against the specific dosing claims)
- Using a daily dose that is not within “2400 mg/day or 2403 mg/day” or not within “1600 mg/day or 1602 mg/day.”
- Avoiding the specified sequence where pirfenidone is discontinued until biomarkers are normalized (if targeting dependent claims).
- Dosing outside “three times per day with food” (again most relevant to dependent claims).
- Using a biomarker strategy that does not match dependent biomarker selections (ALT/AST only; or ALT/AST plus bilirubin/alkaline phosphatase).
What remains hard to avoid
- The trigger condition: a grade 2 liver biomarker abnormality after pirfenidone administration.
- The indication: IPF.
- The drug: pirfenidone.
Those common anchors make method-claim avoidance more difficult if a competitor or provider uses the same clinical management scheme and dose thresholds.
How does US 7,635,707 fit into the broader pirfenidone patent landscape in the US?
Answer: Based on claim content, US 7,635,707 is positioned in the “label-aligned management” layer rather than new chemical entity or broad use. It targets patient management for a safety signal using dose-specific re-initiation steps and biomarker monitoring.
Likely adjacency in the pirfenidone US estate (categories, not specific numbers)
Even without enumerating every related US patent, the patent landscape for pirfenidone in IPF typically clusters into:
- Composition/formulation patents (drug product characteristics, dosing formulations, handling).
- Medical use patents (IPF treatment methods, dose regimens, or patient subset regimens).
- Method-of-treatment and dose-management patents (titration, dose interruption, re-initiation after adverse events).
- Safety monitoring patents (biomarker monitoring, liver monitoring schedules, management algorithms).
US 7,635,707 sits in category 3 with claim elements that overlap with category 4 through ALT/AST/bilirubin/alkaline phosphatase monitoring and normalization endpoints.
When does US 7,635,707 lose exclusivity? (expiration and exclusivity framework)
Answer: None can be derived from your prompt because no filing date, priority date, maintenance status, or listed term adjustments are provided.
What determines enforceable end-of-term in the US method patent context
- Patents expire based on utility term from the earliest US non-provisional effective filing date (plus any adjustments).
- Exclusivity regimes (e.g., regulatory exclusivity) typically do not extend method patents; method patent enforceability is primarily term-driven.
- In litigation, the operative date is the patent expiration and any terminal disclaimers.
Does US 7,635,707 affect generic or label modifications? (Paragraph IV and FDA risk)
Answer: The patent is a method-of-use claim type. It typically becomes relevant to generics if a generic’s intended use in label and/or promotional instructions reasonably read on the patented method and the company seeks marketing approval without carving out the patented method.
How method patents typically create FDA litigation pressure
- If a generic files an ANDA referencing the listed reference product and certifies for the method patent, the FDA approval process turns on whether the method claims are omitted, carved out, or successfully challenged.
- Even if a generic product is bioequivalent, method patents can still be asserted based on how clinicians are expected to use dosing regimens.
Which patent-claim features are most valuable in litigation for US 7,635,707?
Answer: The most litigable features are the ones that can be shown in clinical practice and are tied to objective measurements and dose thresholds.
Highest-evidentiary value claim limitations
- Grade 2 liver biomarker abnormality after pirfenidone (objective, medical record-based).
- Dose thresholds (2400/2403 mg/day and 1600/1602 mg/day).
- Three-times-daily with food (routine administration pattern, often captured in regimen orders).
- Normalization endpoint and discontinuation (EHR and lab history).
- Biomarker measurement during step (a) (lab monitoring documentation).
- Biomarker identity options (ALT/AST; optionally bilirubin/alk phos).
Key Takeaways
- US 7,635,707 is a pirfenidone IPF method-of-administration patent centered on re-initiation dosing after a grade 2 liver biomarker abnormality that occurs after prior pirfenidone exposure.
- Independent coverage is split into two fixed daily-dose regimes: 2400/2403 mg/day (claim 1) and 1600/1602 mg/day (claim 7).
- Dependent claims strengthen enforcement by adding operational steps: hold until biomarkers normalize, three-times-daily with food, biomarker measurement during dosing, and defined biomarker panels (ALT/AST and optionally bilirubin/alkaline phosphatase).
- The optional stepwise intermediate dosing at ~800/801 mg/day for about a week (claims 9 and 10) creates a structured titration pathway that is harder to avoid if clinical practice mirrors the claimed sequence.
FAQs
-
What regimen does US 7,635,707 require after grade 2 ALT/AST elevation on pirfenidone?
It requires administering pirfenidone to an IPF patient with grade 2 liver biomarker abnormality after prior pirfenidone, at 2400/2403 mg/day (claim 1) or 1600/1602 mg/day (claim 7), with dependent options for discontinuation until normalization and three-times-daily dosing with food.
-
Can a protocol that uses only ALT/AST monitoring avoid US 7,635,707?
The patent includes dependent embodiments limited to ALT/AST only (claims 6 and 14), so using only ALT/AST does not, by itself, avoid coverage.
-
Does US 7,635,707 cover holding pirfenidone before re-initiation?
Yes. Dependent claims include discontinuing pirfenidone prior to dosing until liver biomarkers are within normal limits (claims 2 and 8), and a stepwise hold/resume scheme involving about one week at the reduced dose (claims 9 and 10).
-
Is “three times per day with food” required for all claims?
No. It is a dependent limitation (claims 3 and 11). Independent claims as provided do not include that restriction.
-
What dose is protected as the reduced intermediate step in US 7,635,707?
The patent explicitly recites about 800 mg/day or 801 mg/day for about one week or until biomarkers normalize (claims 9 and 10), as part of the 1600/1602 mg/day method family.
More… ↓
⤷ Start Trial
|
